| 2026-08-11 | Press release | Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-07 | SEC filing | Form S-1 |
| 2026-07-17 | Press release | Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair |
| 2026-07-15 | Press release | Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout |
| 2026-07-15 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-14 | Deck | Study ‘207’ Phase 2 Topline Open Label Data in Females with Mild-to-Moderate Pattern Hair Loss |
| 2026-07-14 | Press release | Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss |
| 2026-06-09 | Deck | Tomorrow’s Aesthetic and Dermatological Solutions Today Corporate Presentation June 2026 |
| 2026-05-28 | Press release | Veradermics to Present at Upcoming June Investor Conferences |
| 2026-05-27 | Press release | Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research |
| 2026-05-14 | Press release | Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium |
| 2026-05-12 | Press release | Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-01 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-29 | Press release | Veradermics Announces Pricing of Upsized Public Offering and Private Placement |
| 2026-04-27 | Deck | Study 302 Phase 2/3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss |
| 2026-04-27 | Press release | Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss |
| 2026-04-27 | Press release | Veradermics Announces Launch of Public Offering |
| 2026-04-27 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-27 | SEC filing | Form S-1 |
| 2026-04-26 | Press release | Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss |
| 2026-03-30 | Press release | Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Upd |
| 2026-03-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-30 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-18 | Press release | Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting |
| 2026-03-03 | Press release | Veradermics to Participate in Upcoming March Investor Conferences |
| 2026-02-09 | Press release | Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss |
| 2026-02-05 | 8-K | Form 8-K, Item 5.03 |
| 2026-02-04 | Document | Investor document · Feb 2026 |
| 2026-01-28 | SEC filing | Form S-1/A |
| 2026-01-09 | SEC filing | Form S-1 |